Clinical Trial Update: Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating intraperitoneal paclitaxel in combination with the NALIRIFOX regimen for pancreatic ductal adenocarcinoma with peritoneal carcinomato…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma
• Peritoneal Carcinomatosis

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Intraperitoneal Paclitaxel (paclitaxel)
• Leucovorin (folinic acid)
• Onivyde (liposomal irinotecan) (liposomal irinotecan)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Status: RECRUITING